The Association of Biotech Led Enterprises(ABLE), the voice of the biotechnology industry in India, has urged for a series of reforms to propel the sector in the next phase of its growth.

The important one among them includes the ones pertaining to finance — upto Rs 5,000 crore biomanufacturing fund for soft loans at 4-6 per cent with a two-year moratorium and five-year tax holiday from date of commercialisation; larger SEZs specifically meant for biologics, including biotech drugs under the ‘free medicines scheme’ being contemplated by the Government of India;